Tag: Biomarkers
-
Immunotherapy Advances in SCLC: Promise, Limits, and the Biomarker Challenge
Current gains from immunotherapy in small cell lung cancer (SCLC) Immunotherapy has altered the treatment landscape for SCLC, offering meaningful efficacy where options were once limited. Checkpoint inhibitors that unleash the body’s immune system to attack cancer cells have demonstrated survival benefits in certain patients and disease settings, particularly when used in first-line combinations or…
-
Immunotherapy Advances in SCLC: Promise, Limitations, and the Biomarker Gap
Immunotherapy Advances in Small Cell Lung Cancer (SCLC): A Quiet but Persistent Shift Small cell lung cancer has long challenged clinicians with its aggressive biology and historically limited treatment options. In recent years, immunotherapy has emerged as a meaningful, if nuanced, addition to the standard of care. The story is not a single triumph but…
-
Immunotherapy Advances in SCLC: Promise, Limitations, and Biomarker Needs
Overview: Immunotherapy’s Emerging Role in SCLC Small cell lung cancer (SCLC) has long challenged clinicians with its aggressive biology and tendency for rapid relapse. In recent years, immunotherapy has emerged as a beacon of hope, offering meaningful efficacy gains in several lines of treatment. This article reviews the current state of immunotherapy in SCLC, highlighting…
-
Oncomarkers Awareness Day: Advancing Precision Oncology Through Biomarker Science
Introduction: A Global Day for Biomarker Science Oncomarkers Awareness Day, first observed on November 13, 2025, marks a milestone in the cancer care landscape. This international observance highlights how biomarkers—the measurable indicators of biological processes—are shaping precision oncology. By providing richer diagnostic insights, guiding therapy choices, and monitoring treatment response, biomarkers are helping clinicians tailor…
-
Scientist Cracks 50-Year Riddle and Wins Prestigious Prize
Groundbreaking Breakthrough Earns Top Prize In a moment many scientists dream of, a solitary room, a hum of equipment, and a single data point changed the trajectory of a young researcher’s career. Uche Medoh won the 2025 Science & SciLifeLab Prize for Young Scientists after cracking a 50-year-old riddle that has haunted the field. The…
-
Genomic Testing for NSCLC: Insights from the AONN+ Conference for Oncology Navigators
Understanding genomic testing in NSCLC Genomic testing for non-small cell lung cancer (NSCLC) has evolved from a optional add-on to a cornerstone of personalized care. At the recent AONN+ conference, a focused session explored how oncology nurses, advanced practitioners, and navigators can effectively use biomarker testing to inform treatment decisions across NSCLC subtypes. The goal…
-
Genomic Testing for NSCLC: Session at AONN+ Conference Delivers Insights for Oncology Navigators
Overview: Why Genomic Testing in NSCLC Matters for Navigators Genomic testing has become a cornerstone of non-small cell lung cancer (NSCLC) management. At the AONN+ conference, a dedicated session offered practical insights for oncology nurses, advanced practitioners, and navigators who guide patients through complex diagnostic and treatment pathways. The session emphasized that understanding which biomarker…
-
Multi-System Biomarkers for Suicide Risk in MDD: Erythroid, Inflammation, and Metabolism
Introduction: The Need for Multi-System Biomarkers in MDD Major Depressive Disorder (MDD) remains a leading cause of disability worldwide, with suicide risk representing a critical and urgent challenge for clinicians. Traditional risk assessment often relies on clinical history and self-reported symptoms, which can miss biologically meaningful signals. Emerging research points to a multi-system model of…
-
Multi-system Biomarkers for Suicide Risk in Major Depressive Disorder: Erythroid, Inflammatory, and Metabolic Integration
Introduction: The Need for Multi-system Biomarkers in MDD Major Depressive Disorder (MDD) remains a leading cause of disability worldwide, with suicide risk representing a critical and urgent concern. Traditional risk assessment relies heavily on clinical history and self-reported symptoms, which can fail to capture dynamic biological processes that contribute to suicidality. Emerging evidence suggests that…
-
Multi-System Biomarkers for Suicide Risk in Major Depressive Disorder
Understanding the Need for Multi-System Biomarkers in MDD Major Depressive Disorder (MDD) remains a leading cause of disability worldwide, with suicide risk presenting one of its most urgent clinical challenges. Traditional risk assessments rely on psychosocial factors and clinical history, but they often fail to capture the biological underpinnings that can signal imminent danger. A…